(NASDAQ: ANNX) Annexon's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Annexon's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ANNX's revenue for 2025 to be $6,902,942,252, with the lowest ANNX revenue forecast at $6,902,942,252, and the highest ANNX revenue forecast at $6,902,942,252. On average, 3 Wall Street analysts forecast ANNX's revenue for 2026 to be $1,648,170,716, with the lowest ANNX revenue forecast at $886,455,394, and the highest ANNX revenue forecast at $2,193,099,422.
In 2027, ANNX is forecast to generate $13,583,173,557 in revenue, with the lowest revenue forecast at $6,812,980,195 and the highest revenue forecast at $21,941,965,200.